APA (7th ed.) Citation

E, S., Y, L., J, Z., G, R., K, J., C, O., . . . ES, Y. (2026). CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy. Journal of the National Comprehensive Cancer Network : JNCCN, 24(3.5), . https://doi.org/10.6004/jnccn.2025.7190

Chicago Style (17th ed.) Citation

E, Stringer-Reasor, et al. "CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy." Journal of the National Comprehensive Cancer Network : JNCCN 24, no. 3.5 (2026). https://doi.org/10.6004/jnccn.2025.7190.

MLA (9th ed.) Citation

E, Stringer-Reasor, et al. "CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 24, no. 3.5, 2026, https://doi.org/10.6004/jnccn.2025.7190.